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Abstract: Delivery of small interfering RNA (siRNA) provides one of the most powerful strategies
for downregulation of therapeutic targets. Despite the widely explored capabilities of this strategy,
intracellular delivery is hindered by a lack of carriers that have high stability, low toxicity and
high transfection efficiency. Here we propose a layer by layer (LBL) self-assembly method to
fabricate chitosan-coated gold nanoparticles (CS-AuNPs) as a more stable and efficient siRNA
delivery system. Direct reduction of HAuCl4 in the presence of chitosan led to the formation of
positively charged CS-AuNPs, which were subsequently modified with a layer of siRNA cargo
molecules and a final chitosan layer to protect the siRNA and to have a net positive charge for good
interaction with cells. Cytotoxicity, uptake, and downregulation of enhanced Green Fluorescent
Protein (eGFP) in H1299-eGFP lung epithelial cells indicated that LBL-CS-AuNPs provided excellent
protection of siRNA against enzymatic degradation, ensured good uptake in cells by endocytosis,
facilitated endosomal escape of siRNA, and improved the overall silencing effect in comparison
with commercial transfection reagents Lipofectamine and jetPEI®. Therefore, this work shows that
LBL assembled CS-AuNPs are promising nanocarriers for enhanced intracellular siRNA delivery
and silencing.
Keywords: gold nanoparticles; Chitosan; layer by layer assembly; siRNA; gene delivery; endoso-
mal escape
1. Introduction
Small interfering RNA (siRNA) is a powerful therapeutic technology which induces
post-transcriptional gene silencing via translation inhibition or by cleavage of the target
mRNA by incorporating into the RNA-induced silencing complex (RISC) in the cyto-
plasm [1,2]. Fast enzymatic digestion, limited cellular uptake, inefficient release from
endosomes, and lack of cell-specific targeting are the major obstacles of using naked (free)
siRNA [3–5]. Thus, the therapeutic application of siRNA molecules requires suitable
carriers to allow them to be delivered inside target cells in a safe and effective manner.
Many different delivery systems have been explored to date. These include viral [5] and
non-viral vectors [6,7], each of which come with their own set of advantages and disad-
vantages. For example, although viral vectors are highly efficient, they are associated with
safety concerns such as inherent immunogenicity [8], mutagenesis [9], oncogenic potential,
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and inflammation [10]. These concerns have triggered the development of non-viral vectors
for siRNA delivery including cationic lipids, polymers, peptides and inorganic nanoparti-
cles [7,11,12]. While non-viral vectors are considered to be safer with a reduced immuno-
genic response, they come with their own drawbacks. For instance, cationic liposomes
can suffer from low colloidal stability, difficulties in controlled release, fast elimination in
the body, and poor targeting [13]. Polypeptides for gene delivery have limited efficiency
and are associated with toxic side effects [14]. In addition, cationic polymer-based carriers
can suffer from low stability [15] as well as poor cell recognition and internalization [16].
In spite of those challenges, non-viral vectors remain of great current interest given their
better safety profiles and ease of production at an affordable costs [17].
One of the most widely used polymers for the design of nanocarriers for siRNA deliv-
ery is chitosan [18–20]. Chitosan is a linear biopolymer consisting of randomly repeating
D-glucosamine and N-acetyl-d-glucosamine units [21]. Chitosan is a weak polybase with
a pKa around 6.5 which offers the advantage of being biodegradable and biocompatible
while at the same time being highly positively charged at a pH below the pKa so that it can
easily form electrostatic complexes with nucleic acids [22]. On the downside, it suffers from
poor stability [23,24] and an undefined structural composition [25]. While improvements
have been suggested by making blends with other polymers or modifying its chemical
structure [23,26], there is still a need for increasing the stability of chitosan as a gene de-
livery vehicle. Inorganic nanoparticles like gold nanoparticles (AuNPs) have attracted
great interest because of several advantages including their simple synthesis, tunable size
and surface properties, good biocompatibility, and multifunctional capabilities [27–29].
These unique properties make AuNPs attractive stabilizing scaffolds for gene delivery ve-
hicles. In particular, AuNPs can be used as scaffolds for layer-by-layer (LBL) self-assembly,
which is a widely used technique to deposit multiple layers of positively and negatively
charged polymers onto surfaces of films or nanoparticles [30–32]. Such hybrids of cationic
polymers and inorganic nanoparticles combine the advantages of both systems to achieve
increased gene delivery efficacy [33]. For instance, LBL assembled AuNP-siRNA have
been prepared with polymers that can induce endosomal escape, such as polyethylen-
imine (PEI) [34–38]. However, release of siRNA in the cellular cytoplasm remains limited
due to the high binding affinity between AuNPs-PEI and siRNA [39]. In addition, PEI is
often associated with high cytotoxicity due to inducing membrane perturbations and
chromosome aberrations [40].
Therefore, in this study we propose LBL assembled AuNP-siRNA in combination
with chitosan as a biocompatible and biodegradable cationic polymer to obtain highly
stable gene delivery carriers for efficient intracellular siRNA delivery. AuNPs capped
with chitosan (CS-AuNPs) are synthesized by using chitosan as both the reducing and
stabilizing agent [41,42]. Next, negatively charged siRNA is incorporated as the next layer
on top of the positively charged CS-AuNPs. Finally, a third chitosan layer is applied to
protect the siRNA and endow the particles with a net positive charge which allows them to
easily adsorb to the negatively charged cell membrane, hence facilitating endocytic uptake.
Long term stability in storage buffer, stability in different media, and siRNA release
are investigated. siRNA gene silencing is subsequently evaluated in H1299 cells stably
expressing green fluorescent protein (H1299-eGFP) (as shown in Scheme 1) as a model
that allows for an easy readout of siRNA silencing. Cellular uptake, endosomal escape
transfection efficiency and cell viability are all studied. We find that the here presented
AuNP-based carriers show better stability and efficacy than commercial transfection agents
(Lipofectamine (cationic lipid mediated transfection) and jetPEI® (cationic polymer)) or
nanocarriers prepared from chitosan alone (CSNPs).
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Scheme 1. Schematic representation of LBL-CS-AuNPs for siRNA delivery. Under normal conditions, H1299-eGFP
cells continuously express enhanced Green Fluorescent Protein (eGFP). When LBL-CS-AuNPs are taken up by cells via
endocytosis, chitosan can induce endosomal escape. Then, the released siRNA (si-eGFP) is processed by the RNA-induced
silencing complex (RISC), which targets and cleaves GFP-mRNA. The cleavage of GFP-mRNA leads to decreased GFP
expression and a diminished green fluorescence intensity of H1299-eGFP cells.
2. Results
2.1. Preparation and Characterization of Chitosan-Capped AuNPs (CS-AuNPs)
By direct reduction of aqueous HAuCl4 solution with chitosan (Figure 1A), spher-
ical gold nanoparticles were synthesized as confirmed by the appearance of localized
surface plasmon resonance (LSPR) at 524 nm in Figure 1B. In order to remove unreacted
chitosan from the samples, CS-AuNPs were washed by centrifugation at 22,000× g, 4 ◦C,
for 1 h and then dispersed in ddi. water for further use. The position of the LSPR band
did not change after the washing step, indicating that the CS-AuNPs did not aggregate
during the purification step. The hydrodynamic diameter of CS-AuNPs was measured
in ddi. water and showed an average diameter of 40 ± 5 nm with PDI = 0.24 (Figure 1C).
As expected, the CS-AuNPs were positively charged and the zeta potential was 26 ± 3 mV
(Figure 1C inset), which suggested that chitosan was present on the CS-AuNPs surface as
capping agent.
The morphology and size of CS-AuNPs were determined by transmission electron
microscopy (TEM), as shown in Figure 1D. The size distribution indicates an average
particle core size of 15 ± 1 nm, calculated by image processing for more than 800 particles
(Figure 1D inset). TEM images confirmed that the CS-AuNPs have a spherical morphology.
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Figure 1. Characterization of Chitosan-capped AuNPs (CS-AuNPs), (A) Schematic representation
of the synthesis of AuNPs using chitosan as a capping and reducing agent. (B) UV-Vis spectra of
CS-AuNPs before and after washing of unreacted chitosan by centrifugation. (C) Representative
hydrodynamic size distribution of CS-AuNPs, measured by DLS. The grey curve is the corresponding
cumulative distribution. The inset shows the zeta potential distribution. (D) TEM images of CS-
AuNPs confirming the formation of spherical nanoparticles, which were faceted (inset). The size dis-
tribution from measuring >800 nanoparticles revealed an average particle core size of 15.0 ± 0.5 nm.
(E) FTIR spectra of Chitosan and CS-AuNPs, confirming successful capping of the NPs by Chitosan.
(F) UV-Vis spectra of CS-AuNPs in different media and pH conditions as indicated in the legend.
In order to confirm the presence of chitosan on the surface of CS-AuNPs, we charac-
terized the obtained NPs by Fourier-transform infrared (FTIR) spectroscopy as shown in
Figure 1E. The characteristic bands of chitosan (3373 cm−1 = N-H, O-H stretching band,
2853 cm−1 = C-H stretching band, 1537 cm−1 = N-H, and 1063 cm−1 = C-O stretching
band) [43,44] could indeed be observed in the CS-AuNPs infrared spectrum.
For evaluation of the stability of CS-AuNPs, the UV-Visible spectrum of CS-AuNPs
was measured in different media (PBS, DMEM and HEPES) and water at different pH
values (4.0, 7.4 and 9.0) after 1h incubation. The LSPR position of CS-AuNPs (Figure 1F)
only shifted slightly when exposed to the different media and pH conditions. The effect
of the refractive index of the different media on the LSPR peak shift was investigated
by Mie theory. Figure S1B in the supporting information shows the simulated extinction
cross-section spectra of 15 nm AuNPs performed with reported refractive indexes (nr) of
PBS (nr = 1.3348) and DMEM (nr = 1.3370) [45]. As can be seen in the figure, the simulations
do not depict appreciably changes of the position of the maximum of the LSPR peak with
respect of calculations performed in water (nr = 1.33), arguably due to similar refractive
index values between the evaluated media. The experimental shifts observed on the LSPR
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peak are more likely to be linked to complex local changes of the refractive index due to
changes on the macromolecular disposition of the polymeric layers as a function of ion
concentration and pH. Combined with the absence of spectral features at higher wave-
lengths due to plasmon coupling effects of clustered NPs, this indicated that there was no
aggregation of CS-AuNPs in these conditions and particles remained colloidally stable [46].
2.2. siRNA Loading Capability of the CS-AuNPs
Aimed at obtaining stable CS-AuNPs as a siRNA carrier, a layer-by-layer self-assembly
approach was used. This implied that CS-AuNPs was first be coated with a layer of siRNA
(CS-AuNPs-siRNA) based on electrostatic complexation of negatively charged siRNA to the
cationic CS-AuNPs. In a final step, another layer of chitosan was applied (LBL-CS-AuNPs)
to protect the siRNA and to obtain a net positive zeta potential for efficient interaction with
cells (Scheme 1).
The siRNA loading capacity of the CS-AuNPs was evaluated by mixing siRNA and
CS-AuNPs at different mass ratios of siRNA to Au, ranging from 1:0.5 to 1:12.5. The cor-
responding number of siRNA molecules per nanoparticle is shown in Table 1. As shown
in Figure 2A (left), as more CS-AuNPs are added to the siRNA, the amount of unbound
siRNA in supernatant decreases. In particular, starting from a ratio of 1:7.5 the siRNA
band completely disappeared, indicating that all siRNA was successfully complexed to the
nanoparticles. Complementary to this, when siRNA was dissociated from the carriers by
adding SDS, siRNA bands reappear (Figure 2A right). The signal gradually increases with
intensities becoming comparable to naked siRNA starting from a ratio of 1:7.5. These re-
sults indicate successful siRNA binding onto the CS-AuNPs by electrostatic interactions,
reaching full siRNA loading at ratio 1:7.5. Nevertheless, a weight ratio of 1:10 was selected
for further experiments to guarantee working in conditions with maximal siRNA loading.
Table 1. The different weight ratio and corresponding number ratio of siRNA to CS-AuNPs.








1 The number of siRNA has been calculated based on molecular weight. 2 The concentration of the AuNPs in the
dispersions was estimated from the extinction of the dispersions (Figure S1A).
The process of applying the subsequent layers of siRNA and chitosan on CS-AuNPs
was furthermore monitored by UV-visible spectrometry, dynamic light scattering (DLS),
zeta potential, and TEM. DNA and RNA bases have a broad absorption band in the UV
with maximum absorption around 260 nm. This absorption band was observed in all
the UV-Visible spectra recorded from samples after centrifugation (to remove unattached
siRNA). The extinction increased gradually from ratio 1:0.5 to 1:12.5, which is due on the
one hand to more siRNA being loaded on the CS-AuNPs (at least from ratio 1:0.5 to 1:7.5),
combined with gradually more chitosan being present in the sample due to the increasing
CS-AuNP concentrations and which also absorbs light in the same wavelength region
(Figure 2B). Importantly, the siRNA absorption band remained present after applying the
final CS layer, as can be seen in Figure 2C for particles synthetized at ratio 1:10. It is of
note that no collective plasmonic modes associated to the optical response of clusters of
plasmonic particles were observed at higher wavelengths after deposition of siRNA and
chitosan, indicating that LBL-CS-AuNPs did not aggregate and remained stable in colloidal
dispersion even 7 days after synthesis (Figure S2).
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Figure 2. Synthesis of Layer by Layer (LBL) CS-AuNPs, (A) Agarose gel retardation assay of CS-AuNPs-siRNA complexes
for various mass ratios of siRNA to Au ions (siRNA:Au) (1:0.5, 1:1, 1:2.5, 1:5, 1:7.5, 1:10 and 1:12.5). (B) UV-Vis spectra of
CS-AuNPs-siRNA complexes for various mass ratios. (C) UV-Vis spectra upon sequential adsorption of siRNA and chitosan
onto CS-AuNPs at weight ratio 1:10. (D) Representative particle size and zeta-potential after sequential adsorption of siRNA
and chitosan on CS-AuNPs at weight ratio 1:10. (E–G) TEM images during the three steps of the LBL synthesis process.
The LBL process was also monitored for the LBL-CS-AuNP prepared at ratio 1:10 by
DLS, revealing a gradual increase in hydrodynamic diameter of the NPs (Figure 2D) from
40 ± 5 to 57 ± 3 and 86 ± 4 nm after applying the second and third layer, respectively.
This is also confirmed by a change in zeta potential, starting at 26 ± 3 mV and decreasing
to 10 ± 3 mV upon addition of siRNA and increasing again to 33 ± 3 mV with the final
chitosan layer (Figure 2D). Figure 2E–G show the TEM images after each coating step. A soft
‘halo’ can be seen around the core particles after applying the third layer, again pointing at
successful chitosan coating.
2.3. Preparation and Characterization of Chitosan Nanoparticles (CSNPs)
To better judge the added advantage of using AuNPs as a core particle, we additionally
synthesized nanocarriers made from chitosan alone (CSNPs). siRNA loaded CSNPs were
prepared by mixing different concentrations of siRNA (0–640 nM) with TPP (cross-linker),
while keeping the ratio between Tripolyphosphate (TPP) and CS constant, and then adding
it dropwise into CS solution under magnetic stirring to form nanoparticles (Figure 3A).
As shown in Figure 3B (left), there was no remaining siRNA in the supernatant up un-
til an siRNA concentration of 160 nM, as determined by gel electrophoresis. At higher
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concentrations unbound siRNA appeared, indicating that the maximum loading capacity
was reached. Upon addition of SDS to dissociate siRNA from the CSNPs, fairly identi-
cal amounts of siRNA were indeed found for siRNA concentrations of 160 nM, 320 nM,
and 640 nM (Figure 3B right). These results showed that starting from an siRNA con-
centration of 160 nM, maximum loading capacity was achieved. Further confirmation
was obtained from the UV-Visible spectrum of the supernatants (Figure 3C), showing the
presence of free siRNA only for the two higher concentrations (320 nM and 640 nM),
which was not observed for the case of 160 nM. Therefore, from these results, the formula-
tion with 160 nM siRNA was selected for further experiments. The UV-Visible spectrum of
these siRNA-CSNPs showed increased absorbance around 260 nm compared to CSNPs
(Figure 3D), confirming the presence of siRNA in those nanoparticles. Upon siRNA load-
ing, the nanoparticle’s hydrodynamic diameter slightly increased from 280 ± 13 nm to
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Figure 3. Synthesis of crosslinked CSNPs for siRNA delivery, (A) Schematic representation of CSNPs synthesis with
the crosslinking method. (B) Agarose gel retardation assay of CSNPs with siRNA as a function of siRNA concentration.
(C) UV-Visible spectra of the supernatant obtained after centrifugation, for CSNPs loaded with different amounts of siRNA.
(D) UV-Visible spectra of CSNPs prepared in the absence or presence of 160 nM siRNA. (E) Average hydrodynamic particle
diameter and zeta-potential of CSNPs with or without siRNA.
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2.4. Evaluation of siRNA Release and Stability of Nanoparticles
One of the main motivations to use a nanocarrier that has a solid core was to improve
the stability of the formulations. Evaluation of the size and zeta potential of nanoparticles
over time in water (Figure 4A) showed that CSNPs started to aggregate 48 h after syn-
thesis with noticeable changes in size and zeta potential, while LBL-CS-AuNPs remained
indeed stable for at least a period of 7 days. When suspended in different media for 1
h, the changes observed for LBL-CS-AuNPs were less drastic, even though an increase
in size was observed in water at pH = 9 and in fully supplemented DMEM cell medium
(Figure 4B).
Figure 4. Comparison of siRNA release and colloidal stability between LBL-CS-AuNPs and
CSNPs. (A) Size and zeta potential analysis in DDI water as a function of time for LBL-CS-AuNPs
and CSNPs. (B) The fold change in particle size of LBL-CS-AuNPs and CSNPs in different media
is shown as measured after 1 h incubation. (C) Percentage of siRNA released from LBL-CS-AuNPs
and CSNPs in pH 7.4 HEPES buffer at 37 ◦C as a function of time. Data are represented as mean
± the standard error of the mean for a minimum of three independent experiments. Statistical
significance, with respect to water, is indicated when appropriate (ns = not significant p > 0.05,
* p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001).
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Finally, we also monitored siRNA release over time by using UV-Vis from both
nanoparticle formulations (Figure 4C). After incubation for 12 h, 24 h, and 7 days, 50%,
70%, and 100% of the siRNA was released from CSNPs, respectively. Instead, the release
was only 12%, 18% and 36% for LBL-CS-AuNPs at the same time points. These results
show that siRNA release happens more quickly from CSNPs compared to LBL-CS-AuNPs
under equal conditions. Together we can conclude that the addition of a gold core and
the layer-by-layer design offers clear advantages in terms of both colloidal stability and
binding of siRNA.
2.5. Cytotoxicity, siRNA Delivery and Gene Silencing Efficiency
The biocompatibility of a carrier is an important consideration for its clinical applica-
tion. Therefore, we proceeded to evaluate the cytotoxicity profiles of the nanoparticles on
H1299-eGFP cells by measuring the cell’s metabolic activity (via CellTiter-Glo® lumines-
cent assay) and the percentage of cells that go into apoptosis (via DiIC1(5) and PI staining)
after 4 h incubation with NPs followed by 24 h incubation in fresh cell culture medium
(Figure 5A). When H1299-eGFP cells were incubated with CSNPs, no toxicity was observed
over the whole concentration range studied (Figure 5B). For LBL-CS-AuNPs a constant
weight ratio of 1:10 (siRNA:Au) was used. By increasing the nanoparticle concentration
added to cells, also the effective siRNA concentration was increased, as summarized in
Table 2. The cell viability decreased more quickly for LBL-CS-AuNPs compared to CSNPs
for the same effective siRNA concentration. Correspondingly, the percentage of apoptotic
cells increased more rapidly for LBL-CS-AuNPs, as can be seen in Figure 5C and Figure S3.
We next proceeded to determine the percentage of uptake of LBL-CS-AuNPs and
CSNPs in H1299-eGFP cells. Cell uptake studies were performed using Alexa Flour 647
(AF647) labeled siRNA. Figure 5D shows the percentage of positive cells after 4 h incubation
with nanoparticles prepared with the AF647 labeled siRNA.
Flow cytometry data showed that both NPs were taken up by H1299-eGFP cells with
the percentage of positive cells gradually increasing as a function of the NP concentration
(Figure 5D). At lower concentrations, CSNPs were taken up by more cells, while at the
highest concentrations, both NPs were taken up by near 100% of the cells. A striking
difference was, however, seen in the relative mean fluorescence intensity (rMFI) per cell,
which is related to the number of nanoparticles per cell and which was much higher for
LBL-CS-AuNPs, starting from an siRNA concentration of 16 nM.
To evaluate siRNA transfection by the nanoparticles, eGFP-siRNA was used to eval-
uate downregulation of eGFP in H1299 cells constitutively expressing eGFP. The level
of eGFP protein expression was quantified as the mean green fluorescence intensity of
the entire cell population via flow cytometry. Results from flow cytometry showed that
eGFP expression had indeed decreased 24 h after treatment with the NPs (Figure 5E).
At lower concentrations (2 nM to 24 nM of siRNA) LBL-CS-AuNPs showed more eGFP
downregulation than CSNP, which is likely due to the fact that more LBL-CS-AuNP are
taken up per cell than CSNP. Above 24 nM, the eGFP expression rate increased again for
LBL-CS-AuNP, which is likely related to the toxicity observed for such high concentrations
of LBL-CS-AuNPs.
To better appreciate the performance of LBL-CS-AuNPs, they were compared to two
popular commercial transfection reagents, Lipofectamine and jetPEI® for three siRNA
concentrations (8, 24 and 50 nM). CSNPs were included once more as a reference, next to
naked siRNA, which was included as a negative control. The cell viability after treatment
with LBL-CS-AuNP, Lipofectamine or jetPEI® was not significantly different at siRNA
concentrations of 8 and 24 nM (Figure 6A). At the highest concentration (50 nM), LBL-
CS-AuNPs did become more toxic though. Uptake increased with increasing siRNA
concentrations for all carriers, as expected (Figure 6B). No significant difference was found
between them in terms of the percentage of positive cells for a given siRNA concentration.
The amount of uptake per cell (based on rMFI) was, however, systematically higher for
the commercial transfection reagents. In terms of eGFP downregulation, LBL-CS-AuNP
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performed better (8 nM) or equally well (24 nM and 50 nM) as jetPEI® (Figure 6C and
Figure S4). This is also visually apparent from the supporting confocal microscopy images
in Figure 6D. Compared to Lipofectamine, LBL-CS-AuNP performed similar (8 and 24 nM)
or worse (50 nM). The latter result can likely again be attributed to the relatively high extent
of cytotoxicity by LBL-CS-AuNP at such high concentrations.
Figure 5. [-15]Comparison of siRNA Delivery, gene silencing efficiency and cytotoxicity between LBL-CS-AuNPs and
CSNPs. (A) Schematic representation of the protocol used to evaluation of NPs as siRNA-delivery-carrier. (B) Cell viability
for different effective concentrations of siRNA was measured by CellTiter-Glo® assay after 4 h incubation with LBL-CS-
AuNPs (siRNA:Au 1:10) and CSNPs. (C) Apoptosis for different concentrations was assessed based on mitochondrial
integrity using DiIC1(5) and PI staining. (D) Uptake percentage (= % positive cells) and relative mean fluorescence intensities
of AF647 siRNA labeled LBL-CS-AuNPs on H1299-eGFP cells were determined by flow cytometry. (E) The percent of
GFP expression on H1299-eGFP cells was measure based on the mean GFP fluorescence intensity (MFI) of the cell by flow
cytometry at different concentrations of LBL-CS-AuNPs loaded with GFP-siRNA. Data are represented as mean ± the
standard error of the mean for a minimum of three independent experiments. Statistical significance, with respect to the
not treated control (NTC), is indicated when appropriate (ns = not significant p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001,
**** p ≤ 0.0001).
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1 LBL-CS-AuNPs/mL 2 siRNA/mL 3
2 nM 1.3 µM 1.0 × 1010 1.2 × 1012
4 nM 2.7 µM 2.1 × 1010 2.4 × 1012
8 nM 5.5 µM 4.3 × 1010 4.8 × 1012
16 nM 10.9 µM 8.5 × 1010 9.6 × 1012
24 nM 16.4 µM 1.3 × 1011 1.4 × 1013
32 nM 21.9 µM 1.7 × 1011 1.9 × 1013
50 nM 34.2 µM 2.7 × 1011 3.0 × 1013
64 nM 43.8 µM 3.4 × 1011 3.8 × 1013
1 Au concentration was determined by atomic absorption spectroscopy. 2 The concentration of AuNPs in
the dispersions was estimated from their extinction spectra (Figure S1A). 3 The number of siRNA per mL
was calculated based on Avogadro’s number.
While this confirms efficient cell transfections with LBL-CS-AuNP, their major benefit
comes from the added stability over time. Indeed, incorporation of gold nanoparticles as
a core was motivated by the aim to improve the long-term stability of the formulations.
In line with their previously demonstrated enhanced colloidal stability, their knock-down
efficiency 7 days after synthesis remained unaltered, while all other tested carriers and
transfection reagents had lost most, if not all, of their activity (Figure 6C). This confirms that
the LBL-CS-AuNP design offers superior long-term activity with siRNA downregulation
efficiencies that are up to par with the most popular transfection reagents.
2.6. Evaluation of Endosomal Escape
Successful endosomal escape and release of siRNA into the cytoplasm are known to
be critical prerequisites that a nanocarrier must fulfill for effective siRNA delivery and
the consequent knockdown of specific proteins. To investigate the role of endosomal
escape in the observed transfection efficiencies, confocal fluorescence microscopy studies
were carried out using Alexa Fluor 647-labeled oligonucleotides (AF647 ONs) as cargo
for the different nanoparticles and transfection reagents. When the ONs are incorporated
into the nanocarrier, their fluorescence is mostly quenched, but after release from the
endosomes and dilution into the cytoplasm, their fluorescence enhances again [47,48].
As these ONs accumulate in the nucleus by active transport over time, the presence of a red
fluorescent nucleus is indicative of at least one endosomal escape event having happened
in a particular cell. By counting on the one hand the total number of nuclei in confocal
images (by Hoechst staining) and red fluorescent nuclei on the other hand, the percentage
of cells can be calculated in which at least one endosomal escape event has occurred.
Representative microscopy images obtained after 24 h can be seen in Figure 7A for
LBL-CS-AuNPs, CSNPs, Lipofectamine, jetPEI®, and free AF647 ONs at an effective ON
concentration of 24 nM. The presence of red fluorescent nuclei in the microscopy images
(Figure 7A) confirmed that endosomal escape took place after incubation with every car-
rier. Frequency distributions of the nuclear fluorescence signal in the red channel of all
H1299 cells per condition, quantified from the confocal images (Figure 7B). The percentage
corresponding to the percentage of cells with red nuclei in which escape has happened
was calculated by analysis of at least 500 cells from 20 images for each sample, showing
endosomal escape in 78%, 60%, 48%, and 69% of the cells for LBL-CS-AuNPs, CSNPs,
jetPEI®, and Lipofectamine, respectively (Figure 7C). These percentages show that endoso-
mal escape occurred most efficiently for LBL-CS-AuNPs and Lipofectamine-treated cells,
in line with the transfection results.
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Figure 6. Evaluating the cytotoxicity, uptake and knockdown efficacy of LBL-CS-AuNPs and
CSNPs in comparison with jetPEI® and Lipofectamine as commercial transfection reagents for
siRNA. (A) Cell viability was measured by CellTiter GLO assay after 4 h incubation with the different
carriers at three effective siRNA concentrations (8 nM, 24 nM, and 50 nM). (B) Uptake percentage
(= % pos-itive cells) and relative mean fluorescence intensities of AF647 siRNA labeled carriers on
H1299-eGFP cells were determined by flow cytometry. (C) Percentage of eGFP expression on H1299-
eGFP cells treated with the different carriers at three effective siRNA concentrations (8 nM, 24 nM,
and 50 nM) for both freshly and 7 days after synthesis. (D) Confocal images of H1299-eGFP cells
after treatment with different carriers at 24 nM effective concentration of siRNA. The nuclei stained
with Hoechst 33,342 are shown in blue and the eGFP expression is shown in green in the fluorescence
images. The scale bars correspond to 50 µm. Data are represented as mean ± the standard error of
the mean for a minimum of three independent experiments. Statistical signifi-cance, with respect to
LBL-CS-AuNPs, is indicated when appropriate (ns = not significant p > 0.05, * p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001, **** p ≤ 0.0001).
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Figure 7. Evaluating the role of endosomal escape. (A) Representative confocal images 24 h after
incubation with AF647-ON loaded carriers in the H1299-eGFP cell line. Hoechst nuclei can be seen in
blue, while cells in which endosomal escape occurred show nuclear fluorescence in the red channel
due to the release of AF647 ONs from the endosome to the cytoplasm, which finally accumulate
in the nuclei (white arrows in 3rd column). The scale bars correspond to 50 µm. (B) Histograms
of the red fluorescent intensity of cell nuclei for the different nanocarriers. (C) The percentage of
cells with red nuclei calculated by quantification of at least 500 nuclei. Data are represented as
mean ± the standard error of the mean for a minimum of three independent experiments. Statistical
significance, with respect to LBL-CS-AuNPs, is indicated when appropriate (ns = not significant
p > 0.05, ** p ≤ 0.01, **** p ≤ 0.0001).
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3. Discussion
Chitosan is a biocompatible and biodegradable cationic polysaccharide that can form
complexes with negatively charged nucleic acids through electrostatic interactions [21,49,50].
The amino groups of chitosan can trigger a “proton sponge effect” [51] which contributes
to the endosomal escape of the complex. While PEI does this as well, chitosan is less
cytotoxic than PEI, which can interact with proteins leasing ti the induction of apoptosis [52].
In addition, PEI may cause disruptions in the cell membrane, leading to necrotic cell death
or even chromosome aberrations [40,53,54].
Despite its advantages, there are hardly any available pharmaceutical products based
only on chitosan. This might be a result of the high susceptibility of chitosan to envi-
ronmental factors (humidity, temperature, and pH) [55], structural instability, and lack
of standardized and condensed physical structure. Ongoing research aims at chemically
modifying chitosan’s chemical structure to generate more stable formulations. [18,23].
Our study here was performed from a similar point of view. However, rather than chem-
ically modifying chitosan, we explored if the use of a solid gold core may enhance the
stability of chitosan-based siRNA carriers while still retaining chitosan’s efficient transfec-
tion properties. AuNPs were chosen due to their narrow size distribution, facile synthesis
and stable nature [26]. Using a straightforward LBL assembly method, a chitosan-based
siRNA carrier was designed.
3.1. Nanoparticle Formation, Characterization and Stability
CS-AuNPs have been synthetized in a one-step synthetic method which used chitosan
(CS) both as the reducing agent and stabilizer to generate CS-capped AuNPs. The appear-
ance of a LSPR peak at 524 nm in the UV-Visible spectrum and the absence of plasmonic
bands associated with agglomeration of nanoparticles confirmed that the CS-AuNPs are
stable and do not show aggregation. For the second layer of the LBL coating, different
ratios of siRNA were evaluated for siRNA attachment on the surface of the CS-AuNPs.
Then, a final CS layer was applied to protect the loaded siRNA from preventing fast release
and ensuring efficient uptake by cells and efficient endosomal escape.
Evaluation of siRNA release profiles and colloidal stability indicated that LBL-CS-
AuNPs were more stable than CSNPs which are composed of chitosan alone. We hypothe-
size that the macromolecular organization of the polymer layer on the surface of the gold
nanoparticles confers to their high colloidal stability due to the high cationic charge and
the steric effect of the chitosan.
3.2. Uptake and Transfection Efficiency of Nanoparticles
The biocompatibility of a vector for siRNA delivery is an important consideration.
Investigation of metabolic activity and induction of apoptosis showed that CSNPs in-
duced very little toxicity, even at the highest concentration, while for LBL-CS-AuNPs,
the toxicity gradually increased with increasing concentration. Chitosan is known to be
a biocompatible polymer so the low toxicity by CSNPs is not surprising. The fact that
LBL-CS-AuNP induced more toxicity is very likely due to enhanced cellular uptake, as we
indeed could observe by using fluorescently labeled siRNA. For CSNPs, the rMFI did
not increase substantially with increasing NP concentration, indicating that under the
studied concentrations, the uptake machinery was already saturated. Indeed, it has been
previously suggested that endocytic uptake pathways may be different for particles of
different sizes [56,57]. Therefore, it cannot be excluded that the larger CSNPs are taken
up via a different endocytic pathway, which perhaps may saturate more quickly, than the
smaller LBL-CS-AuNPs. Regardless of the underlying mechanism, enhanced uptake of
LBL-CS-AuNPs resulted in a maximum gene silencing of 76% for LBL-CS-AuNP with
24 nM siRNA, while this remained limited to 49% for CSNPs with 50 nM siRNA.
When comparing transfection efficiencies with two commercial transfection reagents,
jet-PEI and Lipofectamine, it was found that CSNPs showed similar effects as jetPEI®,
while being much less effective than Lipofectamine. LBL-CS-AuNPs at 8 nM, on the other
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hand, performed even better than Lipofectamine, with similar knockdown efficiencies at
higher siRNA concentrations. Importantly, unlike the other carriers (commercial transfec-
tion reagents or CSNPs), LBL-CS-AuNPs were still as functional 7 days after synthesis,
which is yet another demonstration of superior stability of LBL-CS-AuNPs.
3.3. Endosomal Escape Efficiency
In order to explain the experimental observations of the silencing effect, we proceeded
to determine and quantify the endosomal escape capacity of all the NPs evaluated. Af-
ter image analysis (~500 cells for each sample), a direct correlation was found between the
extent of endosomal escape and the transfection efficiencies, indicating that the escape from
endosomes is one of the main factors in the effectiveness of the siRNA delivery carriers
evaluated here.
4. Materials and Methods
4.1. Materials
HAuCl4 and Chitosan (CS, low molecular weight, degree of deacetylation: 80%)
were purchased from Sigma-Aldrich (Overijse, Belgium). RPMI-1640, DMEM (without
phenol red), L-Glutamine, Penicillin/Streptomycin solution (5000 IU/mL penicillin and
5000 µg/mL streptomycin) (P/S), Fetal Bovine Serum (FBS), Trypan Blue, 0.25% Trypsin-
EDTA, and Dulbecco’s phosphate-buffered saline (DPBS) were supplied by Gibco BRL
(Merelbeke, Belgium). CellTiter-Glo® Luminescent Cell Viability Assay was purchased from
Promega (Leiden, The Netherlands). Hoechst 33,342 was purchased from Molecular Probes
(Erembodegem, Belgium). Lipofectamine RNAiMAX reagent was purchased from Invit-
rogen. jetPEI (jetPRIME®) was purchased from Polyplus-transfection® company (Illkirch,
France). siRNA against GFP (si-eGFP, sense strand = 5′-CAAGCUGACCCUGAAGUUCtt-
3′; antisense strand = 5′-GAACUUCAGGGUCAGCUUGtt-3′) and nontargeted siRNA
(si-CTRL, sense strand = 5′-CAAGCUGACCCUGAAGUUCtt-3′; antisense strand = 5′-
GAACUUCAGGGUCAGCUUGtt-3′) were purchased from Eurogentec (Seraing, Belgium).
For uptake experiments, the si-CTRL duplex was labeled with Alexa Fluor 647 dye at
the 5′ end of the sense strand (si-AF647) (Eurogentec, Seraing, Belgium). For endoso-
mal escape AlexaFluor647-labeled oligonucleotides (AF647 ONs) was used (Eurogentec,
Seraing, Belgium).
4.2. Nanoparticles Synthesis
Layer by Layer Gold nanoparticles (LBL-CS-AuNPs):
Core: Gold nanoparticles of 20 nm of diameter capped with chitosan were synthesized
by the reduction of HAuCl4 directly by chitosan [36,38]. Briefly, 200 mL of 0.5% (w/v)
chitosan solution dissolved in 1% (v/v) acetic acid was heated to 100 ◦C under magnetic
stirring and reflux. Next, 85 µL of 25 mM HAuCl4 was added to preheated chitosan
drop by drop and allowed to boil for 1 h under continuous stirring till the color turned
deep red indicating the formation of AuNPs. For removing unreacted material, NPs were
centrifuged at 22,000 g, 4 ◦C, for 1 h and dispersed in deionized water for further use.
Layer by layer assembly of CS-AuNPs: To load negatively charged siRNA molecules
onto the CS-AuNPs as a second layer, CS-AuNPs were resuspended in 10 mM HEPES buffer
with pH = 7 and mixed with siRNA at various weight ratios of siRNA to Au (1:1–12.5)
under continuous stirring (400 RPM) incubated for 1 h. Lastly, a final chitosan layer was
applied by dispersing the nanoparticles in a 0.5% (w/v) chitosan solution, which was
mixed under continuous stirring for another 1 h (LBL-CS-AuNPs). Excess of chitosan and
unattached siRNA was removed by centrifugation at 22,000× g, 4 ◦C, 1 h, and the purified
particles were resuspended in RNase-free water.
Chitosan Nanoparticles (CSNPs):
CSNPs were synthesized via the ionic gelation method as previously reported [58].
Chitosan (CS) solutions were prepared by dissolving CS in 1% v/v acetic acid. The cross-
linking agent, Tripolyphosphate (TPP), was prepared by dissolving TPP in deionized
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water. For siRNA entrapment in CSNPs, siRNA was dissolved in the TPP solution before
adding to the CS solution. The pH of CS solution was adjusted to 5 by adding NaOH
(1 M) after which TPP solution (0.1% w/v) with siRNA (0–640 nM) was added dropwise
into CS solution (0. 2% w/v) under magnetic stirring (5:1 weight ratio of chitosan to
TPP) at 900 RPM for 30 min to form nanoparticles. The formed nanoparticles were then
incubated for another 30 min at room temperature and centrifugated at 15,000 g at 4 ◦C
for 30 min to collect the nanoparticles. The pellets of nanoparticles were resuspended in
RNase-free water.
4.3. Characterization of Nanoparticles
UV–Visible spectroscopy was used to characterize spectral changes in the localized
surface plasmon resonance (LSPR) band of CS-AuNPs in the range of 200–900 nm by using
Thermo Scientific NanoDropTM Spectrophotometers. The hydrodynamic size and zeta
potential of the particles were measured using a Malvern Zetasizer Nano ZS instrument
(Malvern, UK) with a He/Ne laser (633 nm). The morphology and particle size were
analyzed by transmission electron microscopy (TEM) (JEOL, Tokyo, Japan) operating at
80 kV at the VIB-UGent. The samples were prepared by depositing a drop (50 µL) of NPs
on a formvar/C-coated hexagonal copper grid (EMS G200H-Cu) which was allowed to
dry at room temperature and washed 5 times in double-distilled H2O. The average particle
size was determined of counting about 800 particles using Image J. To confirm the presence
of chitosan on CS-AuNPs, their FTIR spectrum was acquired. The washed CS-AuNPs
were freeze-dried (Amsco-Finn Aqua GT4 freeze-dryer (GEA, Köln, Germany)) to obtain
a dry powder and incorporated into pellets after mixing with KBr powder. Spectra were
collected in a BRUKER Vertex 80v Vacuum FT-IR spectrometer (USA) over a range of
4000 cm−1 to 400 cm−1. 100 µL of CS-AuNPs was dissolved in 1 mL aqua regia (mixture
of 36% hydrochloric acid and 65% nitric acid in a 3:1 ratio) after which it was evaporated
under heating to reach a volume of 250 µL, after which it was allowed to cool to room
temperature and diluted with water to a final volume of 10 mL. Finally, the Au content of
those samples was determined by an atomic absorption spectrometer (Varian AA240FS,
Varian, Mulgrave, Australia).
4.4. Evaluation of siRNA Binding to NPs
For the synthesis of CSNPs, various amounts of siRNA were mixed with TPP and after
synthesis, NPs were centrifuged. For evaluation of the siRNA loading capacity of CSNPs,
the supernatant was evaluated with gel electrophoresis in order to quantify unbound
siRNA. For CS-AuNPs, various weight ratios of CS-AuNPs were mixed with siRNA for 1 h
followed by centrifugation at 22,000× g, 4 ◦C, 1 h.
20 µL of the supernatant were mixed with 5 µL of loading buffer and then 20 µL of the
mixture was loaded onto 1% agarose gel (UltraPure Agarose, Invitrogen, Erembodegem,
Belgium) containing 1:10,000 of Gel-REDTM stain (Biotium, Hayward, CA, USA). To evalu-
ate the siRNA loading capacity of the NPs, 5 µL of a 2% SDS solution was added to 20 µL
of NPs to dissociate siRNA from the NPs. The supernatant was prepared in exactly the
same way. After loading the samples onto an agarose gel, electrophoresis was carried
out in a horizontal gel electrophoresis unit (Bio-Rad Laboratories, Richmond, CA, USA)
at 100 V for 30 min in TBE buffer (98 mM Tris, 88 mM Boric acid, 2 mM Na2EDTA with
pH 8). Then the fluorescence bands were visualized using a Kodak digital science camera
(Kodak EDAS 120, Rochester, NY, USA) under UV light (Bio-Rad UV transilluminator 2000,
Richmond, CA, USA).
4.5. Stability and siRNA Release from the NPs
To evaluate the release profile of siRNA, the separation and analysis method described
by Shen et al. was used [59], in which the NPs are directly added into the release medium
and sample separation techniques (centrifugation) are used to separate the dispersed
nanoparticles from the continuous phase at different time intervals. Briefly, the NP suspen-
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sion in 10 mM HEPES buffer at pH 7.4 was incubated for 7 days at 37 ◦C in microtubes
equal in number to the time intervals at which measurements will be performed. At differ-
ent time intervals, one microtube was taken and centrifuged at 22,000× g for 1 h at 4 ◦C.
The concentration of siRNA present in the supernatant was measured using a Thermo
Scientific NanoDropTM Spectrophotometers at 260 nm. The hydrodynamic diameter and
the zeta potential of NPs diluted in DI water and other media was measured over time by
dynamic light scattering (Malvern Zetasizer Nano ZS).
4.6. Cell Culture
H1299 cells stably expressing GFP (H1299-eGFP), which are lung epithelial cells
derived from metastatic lymph nodes (ATCC-CCL 5803), were used as cell model in this
study. In every case, the passage number was kept below 20. H1299-eGFP cells were
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10%
FBS, 2 mM L-Glutamine and 1% pen-strep at 37 ◦C in a 5% CO2 humidified environment.
Culture medium was renewed every other day unless the 80% confluence level was reached.
In this case, the cells were split using 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA).
4.7. Cell Viability Assay
Evaluation of NP cytotoxicity was performed by CellTiter-Glo® luminescent Cell
Viability Assay (Promega, Belgium). For all in vitro studies, selected NPs (1:10 weight
ratio of siRNA:Au for LBL-CS-AuNPs) were diluted in culture medium. Briefly, 100
µL of a suspension of 75,000 cells/mL were added in individual wells of 96-well flat-
bottomed culture plates. After 24 h, different concentrations (2 nM–64 nM, effective siRNA
concentration) diluted in complete RPMI-1640 (100 µL) were used to replace the culture
medium and incubated for 4 h at 37 ◦C. Later, the cells were washed and incubated for
another 24 h with fresh medium. Finally, the cell culture medium was removed and
replaced with 100 µL of pre-heated CellTiter-Glo® reagent and 100 µL of cell culture
medium and shacked 10 min at 120 RPM at room temperature to induce complete cell lysis
and to allow the signal to stabilize. After incubation, 100 µL suspension of each well was
transferred to the white opaque 96 well plates and the luminescence signal was recorded
by a GloMax™ 96 microplate Luminometer (Promega, Belgium). Data are presented as the
mean cell viability (percentage of luminescent signal relative to non-treated cells (NTC) for
each condition) ± standard deviation of the mean for minimum three independent repeats.
4.8. Apoptosis Assay by Flow Cytometry
Induction of apoptosis by the NPs was assessed using propidium iodide (PI) and
dihexaoxacarbocyanine iodide (DiIC1(5)). In brief, cells were plated in 96-well plates at
7500 cells/well. The following day, the medium was replaced with different concentra-
tions of NPs (2 nM–64 nM, effective siRNA concentration) which were diluted in fully
supplemented RPMI-1640. Following 4 h incubation the cells were washed with PBS and
incubated for another 24 h with fresh medium. After 24 h, the medium was removed
and transferred to a U-bottom 96 well plate because the medium could contain dead
cells, which should also be included in the analysis. After dissociating the remaining
attached cells with trypsin solution, the removed cell medium is added again to neutralize
trypsin activity and samples were centrifuged at 500 g for 5 min and the supernatant
was decanted. Cell pellets were resuspended in staining buffer (Flow buffer supple-
mented with 1 µg/mL PI and 10 nM DiIC1(5)) and incubated for 30 min at 37 ◦C and
analyzed by using the CytoFLEX flow cytometer with plate loader for 96-well plates (Beck-
man Coulter, Krefeld, Germany) and CytExpert software. The fluorescence intensity of
DiIC1(5) and PI were measured at 638 nm and 482 nm excitation wavelength and 658 nm
and 608 nm emission wavelength, respectively. The cell population was separated into
three groups; live cells (high intensity of deep red fluorescence, DilC1(5)+/PI-); apoptotic
cells (no fluorescence, DilC1(5)-/PI-); and dead cells (red fluorescence, DilC1(5)-/PI+) with
FlowJo software (Tree Star Inc., Ashland, OR, USA).
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4.9. Quantification of In Vitro Cellular NPs Internalization by Flow Cytometry
NP uptake by H1299 cells was evaluated using Alexa Fluor 647-labeled siRNA (si-
AF647) loaded into NPs (as the second layer for CS-AuNPs). Cells were seeded in 96-well
plates at 9000 cells/well and allowed to attach overnight. The next day, cells were treated
with different concentrations of NPs containing si-AF647 (2 nM–64 nM, effective siRNA
concentration) for 4 h. Next, cells were washed with PBS and detached from the well plates
using trypsin/EDTA 0.25%, diluted with complete cell culture medium, transferred to U-
Bottom 96-well plates, centrifuged at 500 g for 5 min and then cell pellets were resuspended
in flow buffer (DPBS supplemented with 0.1% sodium azide and 1% BSA). Red fluorescence
(638 nm excitation with argon laser and detection with a 660/20 nm bandpass filter) of
samples was measured on a minimum of 10,000 cells using the CytoFLEX flow cytometer.
For calculating rMFI, the following equation was used:
rMFI (relative Mean Fluorescence Intensity) =
MFI of cells treated with si_AF647
MFI of cells treated with non_labeled siRNA
(1)
4.10. Quantification of Transfection Efficiency by Flow Cytometry
H1299 cells stably expressing GFP (H1299-eGFP) were used to evaluate siRNA gene
silencing efficiency of NPs. H1299-eGFP cells were seeded in 96-well plate at 7500 cells per
well. 24 h after seeding, cells were transfected for 4 h with various concentrations of siRNA
(for every si-eGFP condition, a si-CTRL sample was included to account for potential off-
target effects) diluted in fully supplemented RPMI-1640. Next, the medium was removed
and replaced with fresh culture medium. Finally, after 24 h, cells were washed with
DPBS and dissociated by trypsin treatment. For neutralizing trypsin, fully supplemented
RPMI-1640 was added and the suspensions were transferred to a 96-well U-bottomed
plate and centrifuged at 500 g for 5 min. The supernatant was descanted and cells were
resuspended in flow buffer for direct analysis using flow cytometry. For calculating siRNA
gene silencing efficiency, GFP expression was quantified as the following equation:
GFP Expression (%) =
MFI si_eGFP (Mean fluorescence intensity of cells treated with anti GFP siRNA)
MFI si_CTRL (Mean fluorescence intensity of cells treated with CTRL siRNA)
× 100 (2)
where lower GFP expression means higher knockdown efficiency.
4.11. Visualizing eGFP Expression with Confocal Microscopy
H1299-eGFP cells were seeded at 75,000 cells/mL in 35 mm diameter CELLview glass
bottom microscopy dishes (Greiner Bio-One, Vilvoorde, Belgium). On the next day, after re-
moval of the fully supplemented RPMI-1640, the cells were treated with si-eGFP loaded
NPs and compared to benchmark transfection agents (Lipofectamine and jetPEI®) as well
as naked si-eGFP. The incubation time was always 4 h (37 ◦C, 5% CO2) for each condition
after which cells were washed with DPBS. Cells were kept in fresh fully supplemented
RPMI-1640 for an additional 24 h. Next, before confocal imaging, cell nuclei were stained
with Hoechst 33,342 staining (1 mg/mL in H2O; 1000× diluted) in PBS during 15 min at
37 ◦C and washed 2 times with PBS. Then cells were fixed with 4% paraformaldehyde
during 15 min at room temperature. After a double washing step with DPBS, finally one
drop of Vectashield antifade mounting medium (Vector Laboratories, Burlingame, VT, USA)
for preserving fluorescence was added to each sample. A Nikon A1R HD confocal (Nikon,
Japan), equipped with a laser box (LU-N4 LASER UNIT 405/488/561/640, Nikon Benelux,
Brussels Belgium), detectors (A1-DUG-2 GaAsP Multi Detector Unit, GaAsp PMT for
488 and 561 and Multi-Alkali PMT for 647 and 405 nm), and a 20× air objective lens (CFI
plan Apo VC 20×, NA 0.75, WD 1000 µm) (Nikon, Japan). Images were recording using
the NIS Elements software (Nikon, Japan). The 408 and 488 nm laser lines were used to
excite the Hoechst labeled nuclei and the GFP protein, respectively.
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4.12. Visualization and Quantification of Endosomal Escape
Visualization and quantification of endosomal escape were performed based on
a dequenching assay first published by Rehman et al. [48] and further optimized by
Vermeulen et al. [47]. To this end, red-labeled fluorescent oligonucleotides (AF647 ONs)
were incorporated into the NPs instead of siRNA. Upon endosomal escape, the labeled
ONs will spread toward the cytoplasm and finally accumulate in the nucleus. A red flu-
orescent nucleus is then a sign that at least one endosomal escape event happened in a
particular cell.
H1299-eGFP cells were seeded in 35 mm CELLview glass bottom microscopy dishes
(Greiner Bio-One, Vilvoorde, Belgium) at a density of 75,000 cells per mL. Next day,
after removal of the complete medium, the cells were treated with NPs or commercial
transfection agents (Lipofectamine and jetPEI®) containing AF647 ONs. Cells incubated
with naked AF647 ONs without carrier were included as a control. All conditions were
incubated for 4 h (37 ◦C, 5% CO2) and then washed with DPBS after which cells were
kept in fresh fully supplemented medium for an additional 24 h. On the following day,
cell nuclei were stained with Hoechst 33,342 (1 mg/mL in H2O; 1000× diluted) in DPBS
during 15 min at 37 ◦C and washed 2 times with DPBS. Finally, fresh fully supplemented
RPMI-1640 was added, and cells were kept at 37 ◦C in a humidified atmosphere containing
5% CO2 until confocal imaging. The 408 nm, 633 nm and 488 nm laser lines were applied to
excite the Hoechst-labeled nuclei, the fluorescence resulting from AF647 ONs and the GFP
protein, respectively. During data analysis with ImageJ (FIJI) software [60], nuclei were
detected in the blue channel by thresholding (applying the same offset values for every
image), and intensity analysis (mean gray value) of the nuclear fluorescence signal in the
red channel was performed. From this, the percentage of cells with a AF647 ON-positive
nucleus was determined, which is the percentage of cells in which at least one carrier was
able to release its cargo molecules in the cytosol. Data are represented as the percentage of
cells with AF647 ON positive nuclei as determined from at least 500 cells in a minimum of
20 images.
4.13. Statistical Analysis
All experiments were performed in triplicate. All the results are reported as mean± stan-
dard deviation. Statistical comparisons were performed using one-way ANOVA to compare
multiple conditions and student t-test for direct comparison of 2 conditions; a p-value <
0.05 was considered statistically significant.
5. Conclusions
LBL-CS-AuNPs were synthesized by direct reduction with chitosan, and were used as
a core for the design of a siRNA delivery vehicle based on a facile layer-by-layer assembly
method. The results demonstrated that the gold core substantially improves colloidal
stability and siRNA protection, leading to markedly improved siRNA silencing compared
to nanocarriers prepared from chitosan alone. All together, these results indicate that
LBL-CS-AuNPs could become a very promising carrier to deliver siRNA for therapeutic ap-
plications.
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CS-AuNP Chitosan-coated gold nanoparticles
CSNPs Chitosan nanoparticles
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LBL-CS-AuNP Layer by Layer chitosan-coated gold nanoparticles
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PI Propidium iodide
RISC RNA-induced silencing complex
rMFI Relative mean fluorescence intensity
RPMI Roswell Park Memorial Institute
SDS Sodium dodecyl sulfate
si-AF647 Alexa Fluor 647-labeled siRNA
siRNA Small interfering RNA
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